NASDAQ:BTTX Better Therapeutics (BTTX) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 09/23/2026 03:22 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Better Therapeutics Stock (NASDAQ:BTTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Better Therapeutics alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0010Volume2,391 shsAverage Volume10,164 shsMarket Capitalization$4.06 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Better Therapeutics, Inc. was a digital therapeutics company focused on developing prescription software treatments for cardiometabolic diseases. Its platform used cognitive behavioral therapy and other behavior-change techniques to help patients improve habits related to conditions such as type 2 diabetes and cardiovascular disease. The company’s lead product, AspyreRx, formerly known as BT-001, was a prescription digital therapeutic designed to support adults with type 2 diabetes. Delivered through a software application, the treatment aimed to help patients make sustainable changes involving nutrition, physical activity and other lifestyle behaviors. AspyreRx received clearance from the U.S. Food and Drug Administration in 2023. Better Therapeutics was headquartered in the United States and focused primarily on the U.S. healthcare market, working within the prescription digital therapeutics and virtual-care sectors. The company subsequently announced plans to wind down operations and pursue liquidation, and its business activities may no longer be ongoing. Information about its current leadership and operating status is therefore limited.AI Generated. May Contain Errors. Read More Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTTX Stock News HeadlinesBTTX Better Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comJanux Therapeutics Inc (JANX) Receives a Buy from BTIGNovember 7, 2024 | markets.businessinsider.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)This High-Flying Stock Just Became a Better BuyOctober 31, 2024 | fool.comBicara Therapeutics: A Buy Rating on Promising Clinical Progress and Financial FortitudeOctober 9, 2024 | markets.businessinsider.comBetter Therapeutics (OTC:BTTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comViking Therapeutics: Leaping Ahead In The Weight-Loss RaceAugust 22, 2024 | seekingalpha.comPTC Therapeutics Stock Earns RS Rating Upgrade To 83August 19, 2024 | msn.comSee More Headlines BTTX Stock Analysis - Frequently Asked Questions How have BTTX shares performed this year? Better Therapeutics' stock was trading at $0.0001 at the beginning of 2026. Since then, BTTX stock has increased by 0.0% and is now trading at $0.0001. How do I buy shares of Better Therapeutics? Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Better Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Cricut (CRCT), Zomedica (ZOM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT). Company Calendar Today9/24/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Health services Sub-IndustryHealthcare Current SymbolNASDAQ:BTTX CIK1832415 Webmcacquisition.com Phone415-887-2311FaxN/AEmployees40Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares40,580,000Free Float24,233,000Market Cap$4.06 thousand OptionableNo Data Beta0.85 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BTTX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Better Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
